Mereo BioPharma Group plc Result of Annual General Meeting (4233R)
29 6월 2020 - 11:56PM
UK Regulatory
TIDMMPH
RNS Number : 4233R
Mereo BioPharma Group plc
29 June 2020
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Result of Annual General Meeting
London and Redwood City, Calif., June 29, 2020 - Mereo BioPharma
Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a
clinical-stage biopharmaceutical company focused on oncology and
rare diseases, announces that all resolutions proposed at the
Annual General Meeting ("AGM"), held earlier today, were duly
passed. The Board is pleased that all the resolutions received
strong support from shareholders. Full details of the resolutions
can be viewed in the Notice of Meeting on the Company's website at
www.mereobiopharma.com.
The results of the proxy voting in advance of the AGM are shown
below. On the record date there were 213,652,487 ordinary shares of
GBP0.003 each in issue, each carrying one vote per share.
Resolution Votes For Votes at Votes Against Votes Witheld Total Votes Result
Chairman's Cast
Discretion
1 117,742,951 1,059,246 208,112 35,285 119,045,594 Passed
2 117,336,104 1,059,246 575,734 74,510 119,045,594 Passed
3 117,143,339 1,059,246 702,009 141,000 119,045,594 Passed
Richard Jones, the Company's Chief Financial Officer, did not
not stand for re-election as a Director of the Company at the AGM
and has stepped down from the Board following the AGM. Further to
the Company's announcement on March 27, 2020 Mr Jones will remain
in his position as CFO for a transitionary period until he leaves
on July 31, 2020.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for patients with oncology and rare
diseases. Mereo's strategy is to selectively acquire product
candidates for oncology and rare diseases that have already
received significant investment from pharmaceutical and large
biotechnology companies and that have substantial preclinical,
clinical and manufacturing data packages. Mereo's lead oncology
product candidate, etigilimab, an anti-TIGIT, has completed a Phase
1a and Phase 1b for a range of solid tumor types and the second
product candidate, navicixizumab, for ovarian cancer has been
licensed to Oncologie Inc. for up to $300M in milestone payments.
Mereo's lead rare disease product candidate, setrusumab, has
completed a Phase 2b dose-ranging study in adults with osteogenesis
imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics
has been agreed with the FDA and EMA. Mereo's second lead product
candidate, alvelestat, is being investigated in a Phase 2
proof-of-concept clinical trial in patients with alpha-1
antitrypsin deficiency ("AATD"). Mereo plans to form a strategic
partnership for setrusumab prior to initiation of the paediatric
pivotal study.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Adviser
and Broker to Mereo ) +44 (0)20 7894 7000
Phil Davies
Will Goode
Burns McClellan (US Public Relations Adviser
to Mereo) +01 (0) 212 213 0006
Lisa Burns
Steve Klass
FTI Consulting (UK Public Relations Adviser
to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGUKVSRROUNUAR
(END) Dow Jones Newswires
June 29, 2020 10:56 ET (14:56 GMT)
Mereo Biopharma (LSE:MPH)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Mereo Biopharma (LSE:MPH)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
